Medicine and Dentistry
Patient
100%
Human Immunodeficiency Virus
76%
Therapeutic Procedure
25%
Arm
14%
Bone Density
14%
Cell Count
13%
Proteinase Inhibitor
12%
Cells
10%
Lipid
10%
Lopinavir/Ritonavir
9%
Antiretroviral Therapy
9%
Cholesterol
9%
T-Helper Cell
9%
Darunavir Plus Ritonavir
8%
Atazanavir Plus Ritonavir
8%
Marker
8%
Man
8%
Plasma
8%
Monotherapy
7%
Treatment Interruption
7%
RNA
7%
Darunavir
7%
Water-Electrolyte Imbalance
6%
Cardiovascular Risk
6%
Human Immunodeficiency Virus Infection
6%
Tenofovir
6%
Age
6%
Combination Therapy
5%
Prevalence
5%
Wart Virus
5%
Chemotherapeutic Agent
5%
Drug
5%
Association
5%
Dyslipidemia
5%
Screening
5%
Triacylglycerol
5%
Nevirapine
5%
Pharmacology, Toxicology and Pharmaceutical Science
HIV
67%
Proteinase Inhibitor
19%
Darunavir
17%
Darunavir Plus Ritonavir
16%
Lopinavir Plus Ritonavir
12%
Tenofovir
12%
Nevirapine
10%
Drug
10%
Atazanavir Plus Ritonavir
9%
Lipid
9%
Ritonavir
9%
Human Immunodeficiency Virus Infection
8%
Osteoporosis
8%
RNA Directed DNA Polymerase Inhibitor
7%
Cholesterol
7%
Tenofovir Disoproxil
7%
RNA
7%
Monotherapy
6%
Didanosine
6%
Atazanavir
6%
Lamivudine
6%
Pharmacokinetics
6%
Fat
6%
Clinical Trial
6%
Lopinavir
5%
Mitochondrial DNA
5%
Triacylglycerol
5%
Low Density Lipoprotein Cholesterol
5%
Nursing and Health Professions
Patient
31%
Inpatient
10%
Prevalence
10%
Time
7%
Osteoporosis
7%
Control
6%
Procedures
6%
Fat
6%
Highly Active Antiretroviral Therapy
6%
Lamivudine
5%
Drug
5%
Bone Density
5%
Nevirapine
5%
Antiretroviral Therapy
5%
Combination Therapy
5%
